Abstract 314P
Background
There is insufficient evidence on the neoadjuvant use of bevacizumab before interval debulking surgery (IDS) in advanced epithelial ovarian cancer (EOC). We aimed to evaluate the perioperative outcomes in a cohort of women who underwent IDS after receiving bevacizumab added to neoadjuvant chemotherapy (Bev-NACT).
Methods
We retrospectively reviewed the medical records of all women with advanced EOC who underwent IDS between March 2021 and June 2022 after receiving Bev-NACT at Tata Medical Center. Relevant information was extracted from electronic medical records. Appropriate descriptive and survival statistics were used in the analysis.
Results
A total of 33 women underwent IDS after Bev-NACT. Stage IIIC, stage IVA, and stage IVB disease were present in 51.5%, 12.1%, and 36.4% of cases. The most common histology was high-grade serous carcinoma (95%). The median number of bevacizumab cycles received was 3 (2-5). The objective response rate with Bev-NACT was 90.9%. Complete cytoreduction at IDS was achieved in 75.8%. Chemotherapy response score was 1 in 6.1%, 2 in 72.7%, and 3 in 21.2%. Surgical complications of Clavien-Dindo grade 3 or higher occurred in 24.2% of patients. Serious adverse events attributable to bevacizumab occurred in 12.1% (fistula 3%, wound complications 3%, venous thromboembolism 3%, haemorrhage 3%), and the 30-day postoperative death rate was 3%. Median progression-free survival (PFS) was 23 months (95% CI 18-34), and the estimated 3-year PFS rate was 32%.
Conclusions
Bevacizumab added to neoadjuvant chemotherapy before IDS for advanced EOC had an acceptable safety and promising efficacy. Neoadjuvant bevacizumab in advanced EOC needs to be further evaluated in prospective studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
309P - Expression of estrogen receptor is a negative predictive biomarker for immunotherapy with lenvatinib plus pembrolizumab for advanced endometrial cancer with pMMR
Presenter: Hiroyuki Fujii
Session: Poster Display
Resources:
Abstract
310P - A study on the prediction of recurrence site of endometrial cancer using various machine learning techniques
Presenter: Wonkyo Shin
Session: Poster Display
Resources:
Abstract
311P - Circulating cytokines in the differential diagnosis of endometrial cancer
Presenter: Tatyana Abakumova
Session: Poster Display
Resources:
Abstract
312P - Molecular and genetic features of squamous cell carcinoma of vulvar cancer depending on HPV status
Presenter: Visola Navruzova
Session: Poster Display
Resources:
Abstract
313P - Efficacy and safety of oral metronomic chemotherapy in recurrent refractory advanced gynaecological cancer: Experience from regional cancer center of eastern India
Presenter: Ranti Ghosh
Session: Poster Display
Resources:
Abstract
315P - Real-world experience of niraparib as maintenance therapy in newly diagnosed advanced ovarian cancer: A single-center retrospective study
Presenter: Wenxin Liu
Session: Poster Display
Resources:
Abstract
316P - First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study
Presenter: Jing Li
Session: Poster Display
Resources:
Abstract
317P - Attitudes of Israeli gynecologists towards risk reduction salpingo-oophorectomy at hysterectomy for benign conditions and the use of hormonal therapy
Presenter: wisam Assaf
Session: Poster Display
Resources:
Abstract
319P - Survival prediction for ovarian cancer patients from Taiwan cancer registry data
Presenter: Tzu-Pin Lu
Session: Poster Display
Resources:
Abstract
320P - Treatment patterns and outcomes in Indian patients with advanced ovarian cancer: A single center experience
Presenter: Pushpendra Hirapara
Session: Poster Display
Resources:
Abstract